Credit: Shutterstock photoVascular Biogenics, which is developing gene therapies for cancer and small molecules for inflammation, raised $65 million by offering 5.4 million shares at $12, below the range of $13 to $15. Vascular Biogenics plans to list on the NASDAQ under the symbol VBLX. Vascular Biogenics initially filed confidentially on 3/25/2014. Deutsche Bank and Wells Fargo Securities acted as lead managers on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
